Therapeutic results with Cerebrolysin(®) in the treatment of Dementia

Wiener Medizinische Wochenschrift

Volumn 147, Issue 18, 1997, Pages 426-431

  Rainer, M ^a   Brunnbauer, M ^b   Dunky, A ^c   Ender, F ^b   Goldsteiner, H ^d   Holl, O ^b   Kotlan, P ^d   Paulitsch, G ^b   Reiner, C ^e   Stossl J ^e   Zachhuber, C ^f   Mossler H ^g  

^a DANUBE HOSPITAL   (Austria)

^b Wilhelminenspital der Stadt Wien ^*

^c WILHELMINEN HOSPITAL   (Austria)

^d Krankenhaus Wiener Neustadt   (Austria)

^e Research Division   (Austria)

^f KEPLER UNIVERSITY HOSPITAL   (Austria)

^g Research Initiative Ebewe   (Austria)

Author keywords

Cerebrolysin( ); Dementia; Treatment; User observation study

Indexed keywords

CEREBROLYSIN; AMINO ACID; NOOTROPIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD; MULTIINFARCT DEMENTIA; RECALL; TREATMENT OUTCOME; ATTENTION; DEMENTIA; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; NEUROPSYCHOLOGICAL TEST;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMINO ACIDS; ATTENTION; DEMENTIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MENTAL RECALL; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; TREATMENT OUTCOME;

EID: 9844241588     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Akai F, Hiruma S, Sato T, Iwamoto N, Fujimoto M, Iokum, Hasimoto S: Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transection of fimbria-fornix in the rat brain. Histol. Histopath 1992;7:213-221.
2. Baskys A, Wojtowicz M: Effects of brain tissue hydrolysate on synaptic transmission in the hippocampus. Pharmacol Biochem Behav 1994;49:1105-1107.
3. Desmond DW: Vascular dementia: A construct in evolution. Cerebrovasc Br Metabol Rev 1996;8:296-325.
4. Erkinjuntti T, Autio L, Wikström J: Dementia in medical wards. J Clin Epidemiol 1988;41:123-126.
5. Erkinjuntti T: Differential diagnosis between Alzheimer's disease and vascular dementia: evaluation of common clinical methods. Acta Neurol Scand 1987;76:433-442.
6. Fischer P: Differentialdiagnose Demenzen-Depression-Delir. Neuropsychopraktikum 1997;1:4-5.
7. Hachinski VC, Iliffe LD, Zilhka E, duBoulay GH, McAllister VL, Marshall J, Brussel RR, Symon L: Cerebral blood flow in dementia. Arch neurol 1975;32:632-637.
8. Hefti F, Armanini MP, Beck KD, Caras IW, Chen K, Godowski PJ, Goodman LJ, Hammonds RG, Mark MR, Moran P, Nishimura MC Philipps HS, Shih A, Valverde J, Winslow JW: Development of neurotrophic factor therapy for Alzheimer's Disease. In Growth factors as drugs for neurological and sensory disorders. Chichester, Wiley, 1996.
9. Hutter-Paier B, Grygar E, Windisch M: Death of telencephalon neurons induced by glutamate is reduced by the peptide derivative Cerebrolysin. J Neural Transm 1996;47 (suppl): 267-273.
10. Hutter-Paier B, Windisch M, Eggenreich U: Dose-dependant behavioural effects of two protein-free peptide derivatives on the passive avoidance behaviour of rats. Arzneim Forsch / Drug Res 1996;46:242-246.
11. Hutter-Paier B, Windisch M, Eggenreich U: Effects of two protein-free peptide derivatives on passive avoidance behaviour of 24-month old rats. Arzneim Forsch / Drug Res 1996;46:237-241.
12. Jellinger K, Danielczyk W, Fischer P, Gabriel E: Clinico-pathological analysis of dementia disorders in the elderly. J Neurol Sci 1990;95:239-258.
13. Katzman R, Lasker B, Bernstein N: Advances in the diagnosis of dementia: accuracy of diagnosis and consequences of misdiagnosis of disorders causing dementia. In Terry RD (ed): Ageing and the brain. New York, Raven Press, 1988.
14. Levi-Montalcini R, Hamburger V: Selective growth-stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool 1951;116:321-361.
15. Ott A, Breteler MMB, Van Harskamp F, Claus JJ, Van der Cammen TJM, Grobbee DE, Hofman A: Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. Br Med J 1995;310:970-973.
16. Rüther E, Ritter R, Apecechea M, Freytag S, Windisch M: Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with Senile Dementia of the Alzheimer Type (SDAT). Pharmacopsychiatry 1994;27:32-40.
17. Seiger A, Nordberg A, Von Holst H, Backman L, Ebendal T, Alafuzoff I. Amberla K, Martvig P, Herlitz A, Lilja A, Lundquist H, Langstrom B, Meyerson B, Persson A, Viitanen M, Winblad B, Olson L: Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy. Behav Brain Res 1993;57:255-261.
18. Shimazu S, Tachikawa N, Iwamoto N, Itoh T, Komatsu S, Fujimoto M: The neurotrophic and brain protective activity of Cerebrolysin. Neurobiol Ageing 1992;13 (suppl 1): 133.
19. Valouskova V, Francis-Turner L: Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transsection: short-term study. Neurosci Lett 1996;202:193-196.
20. Vereshagin NV, Lebedeva NV, Suslina ZA, Solovyov OI, Priadov MA, Altunina MN: Mild forms of multiinfarct dementia: Evectiveness of Cerebrolysin. Sovjetskaja medicina 1991;11:6-8.
21. Wetterling T, Kanitz RD, Borgis KJ: Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke 1996;27:30-36.
22. Windisch M, Piswanger A: In vitro effects of peptide derivatives and extracts from calf blood on the oxidative metabolism in brain, liver and heart muscle homogenates of the rat. Arzneim Forsch / Drug Res 1985;35:87-89.
23. Xiong H, Wojtowicz M, Baskys A: Brain tissue hydrolysate acts on presynaptic adenosine receptors in the rat hippocampus. Can J Physiol Pharmacol 1995;73:1194-1197.